ArticleOncoimmunology2022

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.

Brian C Avanzino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.